Open AccessIn vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia
Author(s) -
Kim De Keersmaecker,
Idoya Lahortiga,
Nele Mentens,
Cedric Folens,
Leander Van Neste,
Sofie Bekaert,
Peter Vandenberghe,
Marı́a D. Odero,
Peter Marynen,
Jan Cools
Publication year - 2008
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.11894
Subject(s) - leukemia , imatinib , acute lymphocytic leukemia , cancer research , medicine , cell culture , cell , pharmacology , immunology , biology , lymphoblastic leukemia , myeloid leukemia , biochemistry , genetics
Activating NOTCH1 mutations are common in T-cell acute lymphoblastic leukemia. Inhibition of NOTCH1 signaling with gamma-secretase inhibitors causes cell cycle block, but only after treatment for several days. We further documented the effects of gamma-secretase inhibitor treatment on T-cell acute lymphoblastic leukemia cell lines and tested whether combining gamma-secretase inhibitors with other anti-cancer drugs offers a therapeutic advantage.